The global alpha N acetylglucosaminidase market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Alpha N acetylglucosaminidase is a protein associated with Sanfilippo syndrome. It is an enzyme with systematic name alpha-N-acetyl-D-glucosaminide N-acetylglucosaminohydrolase. This enzyme is located in lysosomes, compartments within cells that digest and recycle different types of molecules. The major factor attributable to market growth includes the growing prevalence of Sanfilippo syndrome all over the globe. Sanfilippo syndrome is a rare genetic metabolism disorder. A change in a single gene makes a child's body unable to break down certain carbohydrates (sugars). This leads to serious problems in the brain and nervous system. There is no cure yet for Sanfilippo syndrome. However, alpha-N-acetylglucosaminidase is involved in the stepwise breakdown of large molecules known as glycosaminoglycans (GAGs). 

GAGs are composed of sugar molecules that are linked together to form a long string. To break down these large molecules, individual sugars are removed one at a time from one end of the molecule. Alpha-N-acetylglucosaminidase removes a sugar called N-acetylglucosamine when it is at the end of the GAG chain. Another major factor propelling the growth of the global alpha N acetylglucosaminidase market include the ongoing clinical trials. Clinically, 3 different phenotypes of alpha-N-acetylglucosaminidase have been discovered. Type I is an infantile-onset neuroaxonal dystrophy with rapid neurodegenerative changes manifested by severe psychomotor retardation, cortical blindness, and myoclonal seizures. Lesions are limited to the nervous system, however, there is diffuse osteopenia. Type II is a chronic condition manifested as mild intellectual retardation, angiokeratoma corporis diffusum, and slight facial features. Type III is an intermediate form. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Abeona Therapeutics Inc., and BioMarin Pharmaceutical Inc. among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Alpha N Acetylglucosaminidase Market Report by Segment

By Type

• Lesinidase Alfa
•  ABO-101
• BMN-250
• EGT-201
• Others

By Application

• In-Patient
• Out-Patient

Global Alpha N Acetylglucosaminidase Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa